DOCSLIB.ORG

PROTEOGLYCAN 4: a DYNAMIC REGULATOR of PARATHYROID HORMONE BIOLOGIC ACTIONS By

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PROTEOGLYCAN 4: a DYNAMIC REGULATOR of PARATHYROID HORMONE BIOLOGIC ACTIONS By PROTEOGLYCAN 4: A DYNAMIC REGULATOR OF PARATHYROID HORMONE BIOLOGIC ACTIONS by Chad M. Novince A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Oral Health Sciences) in The University of Michigan 2011 Doctoral Committee: Professor Laurie K. McCauley, Chair Professor Jan C. Hu Professor Russell S. Taichman Associate Professor Hedwig S. Murphy DEDICATION To my parents, Loretta and William To my bothers, Ryan and Zachary ii ACKNOWLEDGEMENTS I express sincere gratitude to all parties that provided me support throughout my doctoral studies in the Oral Health Sciences Ph.D. program. I am deeply appreciative of the time and effort that Dr. Laurie McCauley, my Ph.D. mentor and the chair of my dissertation committee, devoted to my scientific training. I am thankful for her invaluable guidance and support, which empowered me to have a successful Ph.D. training experience. Her sincere passion for the advancement of science and commitment to mentoring is inspiring to developing sc ie ntis t. I acknowledge and thank the members of my dissertation committee; Dr. Laurie McCauley, Dr. Russell Taichman, Dr. Jan Hu, and Dr. Hedwig Murphy for providing me with the direction and support that enabled me to make continual progress throughout my doctoral studies. I am grateful to the members of my committee for unselfishly sharing their expertise and individually meeting with me on a regular basis during my Ph.D. training. The enthusiasm and encouragement conveyed by my committee members towards my doctoral research and training was deeply motivational. I individually acknowledge Dr. Russell Taichman and Dr. Thomas Rosol for their informal mentorship. Scientific interactions with Drs. Taichman and Rosol were formative experiences during my doctoral training. Moreover, their willingness to iii collaborate on scientific projects broadened the scope and impact of my Ph.D research stud ies. I a m ever indebted to the members of Dr. Laurie McCauley’s research laboratory for sharing their vast knowledge and expertise in carrying out scientific research. The enthusiasm for research and discovery that is conveyed by the McCauley lab members provided for an exciting and motivational Ph.D. training experience. I thank Amy Koh, Jan Berry, Glenda Pettway, Xin Li, Jinhui Liao, Flavia Pirih, Serkin Park, Zhengyan Wang, Sun Wook Cho, Fabiana Soki, Megan Michalski, Matt Eber, Payam Entezami, Mallory Van P utten, Naomi Lin, and David Sadler for their friendship and support during my doctoral research training. Individually, I extend sincere thanks to Amy, Megan, and Payam for playing an integral ro le in the progress and success of my Ph.D. research studies. Other individuals I acknowledge for their contributions include Junro Yamashita, Julie Marchesan, Chris Wilson, Ben S inder, Ken Kozloff, C hris Strayhorn, Chris Jung, Taocong Jin, Holly Brown, Ramiro Toribio, Thomas Wronski, and Matthew Warman. Special thanks go to Dr. Charlotte Mistretta, director of the Oral Health Sciences Ph.D. program, for her sincere commitment to the well being and success of the Ph.D. students. Her guidance and enthusiastic support throughout the P h.D. training experience was a source of inspiration that was very meaningful to me. I thank Dr. Robert Bradley fo r his pre-candidate mentors hip. I am grateful to Dean Peter Polverini for taking a sincere interest in my Ph.D. training and professional development. I also extend thanks to Dr. Darnell Kaigler for his positive encouragement and generous advice. iv I acknowledge and thank Patricia Schultz, Janet Riggs, and Diane Lafferty for their guidance and assistance in applying for grants and managing the administrative aspects of my Ph.D. training. Concerning the clinical component of my dual D.D.S./Ph.D. studies I recognize and thank Dr. Marilyn Woolfolk and Dr. Don Heys for facilitating the structuring o f the clinical component of D.D.S./Ph.D. program. Their understanding and willingness to accommodate the demands of the P h.D. curriculum, while never compromising the quality of the D.D.S. curriculum, allowed me to have an optimal undergraduate dental training experience. I extend thanks to Dr. Don Heys, Dr. Philip Richards, and Dr. Bryan Williams for being influential clinical mentors during my D.D.S. training. I also thank Dr. Peter Yaman, Dr. Gisele Neiva, and Dr. John Heys for acting as clinical mentors throughout my graduate dental training in the Graduate Restorative Dentistry Clinic. I acknowledge and extend tremendous gratitude to my brothers Ryan and Zachary, who insp ir ed me to apply to the Oral Health Sciences Ph.D. program. Both Ryan and Zach played formative roles in my scientific development and the progression of my doctoral studies. I relied on them to discuss scientific ideas, trouble shoot problems at the bench, and when necessary to travel to Ann Arbor to assist me in performing scientific experiments. I am ever grateful to my parents for providing unconditional love and support. The ir commitment to professionalism and helping others was influential in my decision to pursue a career in science and healthcare. The unselfish love, support, and positive encouragement provided by my family members played a critical role in the progression and success of my D.D.S./Ph.D. s tud ies. v TABLE OF CONTEN TS DEDICATION…………………………………………………………………………...ii ACKNOWLEDGEMENTS…………………………………………………………….iii LIST OF FIGURES……………………………………………………………………viii LIST OF TABLES……………………………………………………………………….x ABSTRACT……………………………………………………………………………...xi CHAPTER 1 INTRODUCTION……………………………………………………………….1 Problem statement…………………………………………………………1 General hypothesis………………………………………………………...3 Specific aims………………………………………………………………3 Background and significance……………………………………………...4 References………………………………………………………………..12 CHAPTER 2 PROTEOGLYCAN 4, A NOVEL IMMUNOMODULATORY FACTOR, REGULATES PARATHYROID HORMONE ACTIONS ON HEMATOPOIETIC CELLS…………………………………………………..20 Abstract…………………………………………………………………..20 Introduction………………………………………………………………21 Materials and methods…………………………………………………...23 Results……………………………………………………………………29 Disc uss io n………………………………………………………………..35 References………………………………………………………………..50 CHAPTER 3 PROTEOGLYCAN 4: A DYNAMIC REGULATOR OF SKELETOGENESIS AND PTH SKELETAL ANABOLISM………………56 Abstract…………………………………………………………………..56 vi Introduction………………………………………………………………57 Materials and methods…………………………………………………...59 Results……………………………………………………………………66 Discussion………………………………………………………………..75 References………………………………………………………………..93 CHAPTER 4 THE IMPACT OF PROTEOGLYCAN 4 AND PARATHYROID HORMONE ON ARTICULAR CAR TILAGE DEGENERATION………...99 Abstract…………………………………………………………………..99 Introduction……………………………………………………………..100 Materials and methods………………………………………………….102 Results…………………………………………………………………..105 Discussion………………………………………………………………107 References………………………………………………………………119 CHAPTER 5 CONCLUSIONS………………………………………………………………124 Proteoglycan 4, a novel immunomodulatory factor, regulates parathyroid hormone actions on hematopoietic cells………………………………..125 Proteoglycan 4: a dynamic regulator of skeletogenesis and PTH skeletal anabolism……………………………………………………………….127 The impact of proteoglycan 4 and parathyroid hormone on articular cartilage degeneration…………………………………………………..129 Summary………………………………………………………………..130 References………………………………………………………………133 vii LIST OF FIGURES Fig ure 2.1. PTH re gula tio n o f Prg4 mRN A………………………………………………….40 2.2. Histological assessment of bone marrow, liver, and spleen……………………..41 2.3. PTH re gula tio n o f gene expression………………..……………………………..42 2.4. Per ip hera l b lood cells…………………………………………………………….43 2.5. Bone marrow immune cells……………………………………………………...44 2.6. Bone marrow hematopoietic progenitor cells……………………………………45 2.7. Bone marrow megakaryopoietic cells……………………………………………46 2.8. Bone marrow IL6 and SDF-1 express io n………………………………………..47 3.1. PTH re gula tio n o f Prg4 mRN A………………………………………….………82 3.2. Trabecular bone area and volume analysis………………………………………83 3.3 Tibial growth plate, femur length, and bone turnover serum biochemical analysis in young mice…………………………………………………………………….84 3.4. Bone marrow stromal cell (BMSC) in vitro osteoblastogenesis assays…………85 3.5. Proximal tibia bone cell numbers and activity…………………………………...86 3.6. Ad ult Prg4 mice - serum biochemical analysis of bone turnover and mineral homeostasis……………………………………………………………….……...87 3.7. Joint range of motion and animal mobility………………………………………88 3.8. PTH regulation of bone marrow and liver gene expression……………………..89 viii 4.1. Knee joint histopathology…………....................................................................114 4.2. Subchondral bone morphology…………………………………………………115 4.3. Articular cartilage degradation…………………………………………………116 4.4 Chondrocyte apoptosis………………………………………………………….117 4.5. SDF-1 expression in the synovium……………………………………………..118 5.1. Proteoglycan 4 indirectly supports PTH anabolic actions.……...……………...132 ix LIST OF TABLES Table 2.1 Prg4 protein products……………………………………………………………48 2.2 Peripheral blood cells………………………………………………………….....49 3.1 Femur micro-CT analysis………………………………………………………..90 3.2 Bone marrow and liver gene expression…………………………………………91 3.3 Serum biochemical analysis – IGF-I and F GF-2………………………………...92 x ABSTRACT PROTEOGLYCAN 4: A DYNAMIC REGULATOR OF PARATHYROID HORMONE BIOLOGIC ACTIONS By Chad M. Novince Chair: Laurie K. McCauley Intermittent parathyroid hormone (PTH) (1-34) is the only anabolic agent currently approved for the treatment of osteoporo s is in the U.S. PTH (1-34) is under clinical
Load more

Recommended publications
  • Comparative Gene Expression Profiling of Stromal Cell Matrices
    ell Res C ea m rc te h S & f o T h l Journal of Tiwari et al., J Stem Cell Res Ther 2013, 3:4 e a r n a r p u DOI: 10.4172/2157-7633.1000152 y o J ISSN: 2157-7633 Stem Cell Research & Therapy Research Article Open Access Comparative Gene Expression Profiling of Stromal Cell Matrices that Support Expansion of Hematopoietic Stem/Progenitor Cells Abhilasha Tiwari1,2, Christophe Lefevre2, Mark A Kirkland2*, Kevin Nicholas2 and Gopal Pande1* 1CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, India 2Deakin University, Waurn Ponds, Geelong, VIC, Australia Abstract The bone marrow microenvironment maintains a stable balance between self-renewal and differentiation of hematopoietic stem/progenitor cells (HSPCs). This microenvironment, also termed the “hematopoietic niche”, is primarily composed of stromal cells and their extracellular matrices (ECM) that jointly regulate HSPC functions. Previously, we have demonstrated that umbilical cord blood derived HSPCs can be maintained and expanded on stromal cell derived acellular matrices that mimic the complexity of the hematopoietic niche. The results indicated that matrices prepared at 20% O2 with osteogenic medium (OGM) were best suited for expanding committed HSPCs, whereas, matrices prepared at 5% O2 without OGM were better for primitive progenitors. Based upon these results we proposed that individual constituents of these matrices could be responsible for regulation of specific HSPC functions. To explore this hypothesis, we have performed comparative transcriptome profiling of these matrix producing cells, which identified differential expression of both known niche regulators, such as Wnt4, Angpt2, Vcam and Cxcl12, as well as genes not previously associated with HSPC regulation, such as Depp.
    [Show full text]
  • Dickkopf-1 Promotes Hematopoietic Regeneration Via Direct and Niche-Mediated Mechanisms
    ARTICLES Dickkopf-1 promotes hematopoietic regeneration via direct and niche-mediated mechanisms Heather A Himburg1,7, Phuong L Doan2,7, Mamle Quarmyne1,3, Xiao Yan1,3, Joshua Sasine1, Liman Zhao1, Grace V Hancock4, Jenny Kan1, Katherine A Pohl1, Evelyn Tran1, Nelson J Chao2, Jeffrey R Harris2 & John P Chute1,5,6 The role of osteolineage cells in regulating hematopoietic stem cell (HSC) regeneration following myelosuppression is not well understood. Here we show that deletion of the pro-apoptotic genes Bak and Bax in osterix (Osx, also known as Sp7 transcription factor 7)-expressing cells in mice promotes HSC regeneration and hematopoietic radioprotection following total body irradiation. These mice showed increased bone marrow (BM) levels of the protein dickkopf-1 (Dkk1), which was produced in Osx-expressing BM cells. Treatment of irradiated HSCs with Dkk1 in vitro increased the recovery of both long-term repopulating HSCs and progenitor cells, and systemic administration of Dkk1 to irradiated mice increased hematopoietic recovery and improved survival. Conversely, inducible deletion of one allele of Dkk1 in Osx-expressing cells in adult mice inhibited the recovery of BM stem and progenitor cells and of complete blood counts following irradiation. Dkk1 promoted hematopoietic regeneration via both direct effects on HSCs, in which treatment with Dkk1 decreased the levels of mitochondrial reactive oxygen species and suppressed senescence, and indirect effects on BM endothelial cells, in which treatment with Dkk1 induced epidermal growth factor (EGF) secretion. Accordingly, blockade of the EGF receptor partially abrogated Dkk1-mediated hematopoietic recovery. These data identify Dkk1 as a regulator of hematopoietic regeneration and demonstrate paracrine cross-talk between BM osteolineage cells and endothelial cells in regulating hematopoietic reconstitution following injury.
    [Show full text]
  • Supporting Online Material
    1 2 3 4 5 6 7 Supplementary Information for 8 9 Fractalkine-induced microglial vasoregulation occurs within the retina and is altered early in diabetic 10 retinopathy 11 12 *Samuel A. Mills, *Andrew I. Jobling, *Michael A. Dixon, Bang V. Bui, Kirstan A. Vessey, Joanna A. Phipps, 13 Ursula Greferath, Gene Venables, Vickie H.Y. Wong, Connie H.Y. Wong, Zheng He, Flora Hui, James C. 14 Young, Josh Tonc, Elena Ivanova, Botir T. Sagdullaev, Erica L. Fletcher 15 * Joint first authors 16 17 Corresponding author: 18 Prof. Erica L. Fletcher. Department of Anatomy & Neuroscience. The University of Melbourne, Grattan St, 19 Parkville 3010, Victoria, Australia. 20 Email: [email protected] ; Tel: +61-3-8344-3218; Fax: +61-3-9347-5219 21 22 This PDF file includes: 23 24 Supplementary text 25 Figures S1 to S10 26 Tables S1 to S7 27 Legends for Movies S1 to S2 28 SI References 29 30 Other supplementary materials for this manuscript include the following: 31 32 Movies S1 to S2 33 34 35 36 1 1 Supplementary Information Text 2 Materials and Methods 3 Microglial process movement on retinal vessels 4 Dark agouti rats were anaesthetized, injected intraperitoneally with rhodamine B (Sigma-Aldrich) to label blood 5 vessels and retinal explants established as described in the main text. Retinal microglia were labelled with Iba-1 6 and imaging performed on an inverted confocal microscope (Leica SP5). Baseline images were taken for 10 7 minutes, followed by the addition of PBS (10 minutes) and then either fractalkine or fractalkine + candesartan 8 (10 minutes) using concentrations outlined in the main text.
    [Show full text]
  • Differential Regulation of Proteoglycan 4 Metabolism in Cartilage by IL-1A, IGF-I, and TGF-B1 T
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Osteoarthritis and Cartilage (2008) 16, 90e97 ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved. doi:10.1016/j.joca.2007.05.009 International Cartilage Repair Society Differential regulation of proteoglycan 4 metabolism in cartilage by IL-1a, IGF-I, and TGF-b1 T. A. Schmidt Ph.D., N. S. Gastelum B.S., E. H. Han M.S., G. E. Nugent-Derfus Ph.D., B. L. Schumacher B.S. and R. L. Sah M.D., Sc.D.* Department of Bioengineering and Whitaker Institute of Biomedical Engineering, University of California-San Diego, La Jolla, CA 92093-0412, United States Summary Objectives: To determine (1) if interleukin-1 alpha (IL-1a), insulin like growth factor I (IGF-I), and transforming growth factor-beta 1 (TGF-b1) regulate proteoglycan 4 (PRG4) metabolism in articular cartilage, in terms of chondrocytes expressing PRG4 and PRG4 bound at the articular surface, and (2) if these features of cartilage PRG4 metabolism correlate with its secretion. Methods: Articular cartilage explants were harvested and cultured for 6 days with or without 10% fetal bovine serum (FBS), alone, or with the addition of 10 ng/ml IL-1a, 300 ng/ml IGF-I, or 10 ng/ml TGF-b1. PRG4 expression by chondrocytes in the cartilage disks was assessed by immunohistochemistry (IHC). PRG4 bound to the articular surface of disks was quantified by extraction and enzyme-linked immunosorbent assay (ELISA). PRG4 secreted into culture medium was quantified by ELISA and characterized by Western Blot.
    [Show full text]
  • PRG4) in Modulating Osteoarthritic Synoviocyte Proliferation and Expression of Matrix Degrading Enzymes Ali Alquraini MCPHS University
    Chapman University Chapman University Digital Commons Pharmacy Faculty Articles and Research School of Pharmacy 2017 The Autocrine Role of Proteoglycan-4 (PRG4) in Modulating Osteoarthritic Synoviocyte Proliferation and Expression of Matrix Degrading Enzymes Ali Alquraini MCPHS University Maha Jamal MCPHS University Ling Zhang Rhode Island Hospital Tannin Schmidt University of Calgary Gregory D. Jay Rhode Island Hospital FSeoe nelloxtw pa thige fors aaddndition addal aitutionhorsal works at: http://digitalcommons.chapman.edu/pharmacy_articles Part of the Amino Acids, Peptides, and Proteins Commons, Genetic Phenomena Commons, Other Chemicals and Drugs Commons, and the Pharmaceutical Preparations Commons Recommended Citation Alquraini A, Jamal M, Zhang L, Schmidt T, Jay GD, Elsaid KA. The uta ocrine role of proteoglycan-4 (PRG4) in modulating osteoarthritic synoviocyte proliferation and expression of matrix degrading enzymes. Arthritis Research & Therapy. 2017;19:89. doi:10.1186/s13075-017-1301-5. This Article is brought to you for free and open access by the School of Pharmacy at Chapman University Digital Commons. It has been accepted for inclusion in Pharmacy Faculty Articles and Research by an authorized administrator of Chapman University Digital Commons. For more information, please contact [email protected]. The Autocrine Role of Proteoglycan-4 (PRG4) in Modulating Osteoarthritic Synoviocyte Proliferation and Expression of Matrix Degrading Enzymes Comments This article was originally published in Arthritis Research & Therapy, volume 19, in 2017. DOI: 10.1186/ s13075-017-1301-5 Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 License. Copyright The uthora s Authors Ali Alquraini, Maha Jamal, Ling Zhang, Tannin Schmidt, Gregory D. Jay, and Khaled A.
    [Show full text]
  • PDGF-BB Modulates Hematopoiesis and Tumor Angiogenesis by Inducing Erythropoietin Production in Stromal Cells
    ARTICLES PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells Yuan Xue1, Sharon Lim1, Yunlong Yang1, Zongwei Wang1, Lasse Dahl Ejby Jensen1, Eva-Maria Hedlund1, Patrik Andersson1, Masakiyo Sasahara2, Ola Larsson3, Dagmar Galter4, Renhai Cao1, Kayoko Hosaka1 & Yihai Cao1,5 The platelet-derived growth factor (PDGF) signaling system contributes to tumor angiogenesis and vascular remodeling. Here we show in mouse tumor models that PDGF-BB induces erythropoietin (EPO) mRNA and protein expression by targeting stromal and perivascular cells that express PDGF receptor-b (PDGFR-b). Tumor-derived PDGF-BB promoted tumor growth, angiogenesis and extramedullary hematopoiesis at least in part through modulation of EPO expression. Moreover, adenoviral delivery of PDGF-BB to tumor-free mice increased both EPO production and erythropoiesis, as well as protecting from irradiation-induced anemia. At the molecular level, we show that the PDGF-BB–PDGFR-b signaling system activates the EPO promoter, acting in part through transcriptional regulation by the transcription factor Atf3, possibly through its association with two additional transcription factors, c-Jun and Sp1. Our findings suggest that PDGF-BB–induced EPO promotes tumor growth through two mechanisms: first, paracrine stimulation of tumor angiogenesis by direct induction of endothelial cell proliferation, migration, sprouting and tube formation, and second, endocrine stimulation of extramedullary hematopoiesis leading to increased oxygen perfusion and protection against tumor-associated anemia. Genetic and epigenetic changes in the tumor environment often lead of tumor blood vessels. Such vascular alterations can eventually to elevated amounts of a variety of angiogenic factors that switch on lead to antiangiogenic drug resistance1,14,15.
    [Show full text]
  • Early Growth Response 1 Regulates Hematopoietic Support and Proliferation in Human Primary Bone Marrow Stromal Cells
    Hematopoiesis SUPPLEMENTARY APPENDIX Early growth response 1 regulates hematopoietic support and proliferation in human primary bone marrow stromal cells Hongzhe Li, 1,2 Hooi-Ching Lim, 1,2 Dimitra Zacharaki, 1,2 Xiaojie Xian, 2,3 Keane J.G. Kenswil, 4 Sandro Bräunig, 1,2 Marc H.G.P. Raaijmakers, 4 Niels-Bjarne Woods, 2,3 Jenny Hansson, 1,2 and Stefan Scheding 1,2,5 1Division of Molecular Hematology, Department of Laboratory Medicine, Lund University, Lund, Sweden; 2Lund Stem Cell Center, Depart - ment of Laboratory Medicine, Lund University, Lund, Sweden; 3Division of Molecular Medicine and Gene Therapy, Department of Labora - tory Medicine, Lund University, Lund, Sweden; 4Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands and 5Department of Hematology, Skåne University Hospital Lund, Skåne, Sweden ©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2019.216648 Received: January 14, 2019. Accepted: July 19, 2019. Pre-published: August 1, 2019. Correspondence: STEFAN SCHEDING - [email protected] Li et al.: Supplemental data 1. Supplemental Materials and Methods BM-MNC isolation Bone marrow mononuclear cells (BM-MNC) from BM aspiration samples were isolated by density gradient centrifugation (LSM 1077 Lymphocyte, PAA, Pasching, Austria) either with or without prior incubation with RosetteSep Human Mesenchymal Stem Cell Enrichment Cocktail (STEMCELL Technologies, Vancouver, Canada) for lineage depletion (CD3, CD14, CD19, CD38, CD66b, glycophorin A). BM-MNCs from fetal long bones and adult hip bones were isolated as reported previously 1 by gently crushing bones (femora, tibiae, fibulae, humeri, radii and ulna) in PBS+0.5% FCS subsequent passing of the cell suspension through a 40-µm filter.
    [Show full text]
  • NG2 Proteoglycan in the Diagnosis, Prognosis and Therapy of Gliomas
    Mini Review Int J cell Sci & mol biol Volume 2 Issue 2 - April 2017 Copyright © All rights are reserved by Davide Schiffer DOI : 10.19080/IJCSMB.2017.02.555582 NG2 Proteoglycan in the Diagnosis, Prognosis and Therapy of Gliomas Davide Schiffer*, Laura Annovazzi, Enrica Bovio and Marta Mellai Research Center, Policlinico di Monza Foundation, Italy Submission: February 23, 2017; Published: April 27, 2017 *Corresponding author: Davide Schiffer, Research Center, Policlinico di Monza Foundation, Vercelli, Italy, Tel: ; Fax: ; Email: Abstract expressed during development in glia cells committing themselves to a differentiation. It regulates cell proliferation, migration, invasion and neuronalThe review function concerns through the a crosstalk state of artwith of neuronsNG2 proteoglycan by its extracellular from its firstdomain. description It marks to the its oligodendrocyte utilization in glioma precursor therapy. cells, NG2 differentiate protein is into mature oligodendrocytes, and also astrocytes. It is expressed also in pericytes and it is involved in their relationship with that endothelial cells. NG2 distribution in normal central nervous system and in gliomas is discussed, together with its association with Olig2 and PDGFRa. Recently, it became the focus of attention as a therapeutic target. Various attempts have been made using monoclonal antibodies or RNAi, both in animals and in cell lines. Its ablation resulted in the reduction of glioblastoma cell viability. In children gliomas NG2 distribution is different, but children’s brains are very rich in NG2 cells, so that the possibility of a tumor prevention might be hypothesized. Keywords: NG2; Gliomas; Diagnosis; Therapy Introduction It is activated by ligands through focal adhesion kinase(FAK) Glia cells expressing chondroitin sulfate proteoglycan 4 and mitogen-activated protein kinase(MAPK) and it regulates (CSPG4) are called NG2 (neuron-glia antigen 2) cells and occur cell proliferation, migration, invasion and neuronal function in developing as well as in adult brain.
    [Show full text]
  • Molecular Analysis of the Genetic Heterogeneity Between Primary and Recurrent Glioblastoma
    Syracuse University SURFACE Syracuse University Honors Program Capstone Syracuse University Honors Program Capstone Projects Projects Spring 5-1-2009 Molecular Analysis of the Genetic Heterogeneity Between Primary and Recurrent Glioblastoma Anushi Shah Follow this and additional works at: https://surface.syr.edu/honors_capstone Part of the Biology Commons, and the Genetics and Genomics Commons Recommended Citation Shah, Anushi, "Molecular Analysis of the Genetic Heterogeneity Between Primary and Recurrent Glioblastoma" (2009). Syracuse University Honors Program Capstone Projects. 449. https://surface.syr.edu/honors_capstone/449 This Honors Capstone Project is brought to you for free and open access by the Syracuse University Honors Program Capstone Projects at SURFACE. It has been accepted for inclusion in Syracuse University Honors Program Capstone Projects by an authorized administrator of SURFACE. For more information, please contact [email protected]. Molecular Analysis of the Genetic Heterogeneity Between Primary and Recurrent Glioblastoma A Capstone Project Submitted in Partial Fulfillment of the Requirements of the Renée Crown University Honors Program at Syracuse University Anushi Shah Candidate for B.S. Biology & Psychology and B.A. Anthropology Degree and Renée Crown University Honors May 2009 Honors Capstone Project in: __________Biology__________ Capstone Project Advisor: ____________________________ (Dr. Frank Middleton) Honors Reader: ____________________________ (Dr. Shannon Novak) Honors Director: __ __________________________ Samuel Gorovitz Date: _____________ April 21 st , 2009 Abstract Introduction: Glioblastoma multiforme (GBM) is one of the deadliest forms of brain cancer, and affects more than 18,000 new cases each year in the United States alone. The current standard of treatment for GBM includes surgical removal of the tumor, along with radiation and chemotherapy.
    [Show full text]
  • Ep 2812024 B1
    (19) TZZ _ Z _T (11) EP 2 812 024 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 39/015 (2006.01) C07K 14/445 (2006.01) 11.04.2018 Bulletin 2018/15 (86) International application number: (21) Application number: 13704077.0 PCT/EP2013/052557 (22) Date of filing: 08.02.2013 (87) International publication number: WO 2013/117705 (15.08.2013 Gazette 2013/33) (54) TARGETING OF CHONDROITIN SULFATE GLYCANS TARGETING VON CHONDROITINSULFATGLYCANEN CIBLAGE DE GLYCANES DE SULFATE DE CHONDROÏTINE (84) Designated Contracting States: • MADELEINE DAHLBÄCK ET AL: "The AL AT BE BG CH CY CZ DE DK EE ES FI FR GB chondroitin sulfate A-binding site of the GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO VAR2CSA protein involves multiple N-terminal PL PT RO RS SE SI SK SM TR domains", JOURNAL OF BIOLOGICAL Designated Extension States: CHEMISTRY, AMERICAN SOCIETY FOR BA ME BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, BETHESDA, MD, USA, vol. 286, no. 18, 6 May (30) Priority: 09.02.2012 US 201261596931 P 2011 (2011-05-06), pages 15908-15917, XP002669767, ISSN: 1083-351X, DOI: (43) Date of publication of application: 10.1074/JBC.M110.191510 [retrieved on 17.12.2014 Bulletin 2014/51 2011-03-11] cited in the application • SRIVASTAVA A ET AL: "Var2CSA Minimal CSA (73) Proprietor: Var2 Pharmaceuticals ApS Binding Region Is Located within the N-Terminal 2200 Copenhagen N (DK) Region", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol.
    [Show full text]
  • Genomics of Inherited Bone Marrow Failure and Myelodysplasia Michael
    Genomics of inherited bone marrow failure and myelodysplasia Michael Yu Zhang A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2015 Reading Committee: Mary-Claire King, Chair Akiko Shimamura Marshall Horwitz Program Authorized to Offer Degree: Molecular and Cellular Biology 1 ©Copyright 2015 Michael Yu Zhang 2 University of Washington ABSTRACT Genomics of inherited bone marrow failure and myelodysplasia Michael Yu Zhang Chair of the Supervisory Committee: Professor Mary-Claire King Department of Medicine (Medical Genetics) and Genome Sciences Bone marrow failure and myelodysplastic syndromes (BMF/MDS) are disorders of impaired blood cell production with increased leukemia risk. BMF/MDS may be acquired or inherited, a distinction critical for treatment selection. Currently, diagnosis of these inherited syndromes is based on clinical history, family history, and laboratory studies, which directs the ordering of genetic tests on a gene-by-gene basis. However, despite extensive clinical workup and serial genetic testing, many cases remain unexplained. We sought to define the genetic etiology and pathophysiology of unclassified bone marrow failure and myelodysplastic syndromes. First, to determine the extent to which patients remained undiagnosed due to atypical or cryptic presentations of known inherited BMF/MDS, we developed a massively-parallel, next- generation DNA sequencing assay to simultaneously screen for mutations in 85 BMF/MDS genes. Querying 71 pediatric and adult patients with unclassified BMF/MDS using this assay revealed 8 (11%) patients with constitutional, pathogenic mutations in GATA2 , RUNX1 , DKC1 , or LIG4 . All eight patients lacked classic features or laboratory findings for their syndromes.
    [Show full text]
  • Changes in Gene Expression by Trabecular Meshwork Cells in Response to Mechanical Stretching
    Changes in Gene Expression by Trabecular Meshwork Cells in Response to Mechanical Stretching Vasavi Vittal, Anastasia Rose, Kate E. Gregory, Mary J. Kelley, and Ted S. Acott PURPOSE. Trabecular meshwork (TM) cells appear to sense to 5% of people exhibit pathologic elevations in IOP with changes in intraocular pressure (IOP) as mechanical stretching. subsequent optic nerve damage, even at advanced ages.1,2 We In response, they make homeostatic corrections in the aqueous have hypothesized that TM cells can adjust outflow resistance humor outflow resistance, partially by increasing extracellular over a timescale of hours to days by modulating trabecular ECM matrix (ECM) turnover initiated by the matrix metalloprotein- turnover and subsequent biosynthetic replacement.3–6 Manip- ases. To understand this homeostatic adjustment process fur- ulation of the trabecular activity of a family of ECM turnover ther, studies were conducted to evaluate changes in TM gene enzymes, the matrix metalloproteinases (MMPs), reversibly expression that occur in response to mechanical stretching. modulates outflow facility.7 Inhibition of the endogenous ECM METHODS. Porcine TM cells were subjected to sustained me- turnover, which is initiated by these MMPs, increases the chanical stretching, and RNA was isolated after 12, 24, or 48 outflow resistance. Therefore, ongoing ECM turnover must be hours. Changes in gene expression were evaluated with mi- necessary for homeostatic maintenance of the IOP. In addition, croarrays containing approximately 8000 cDNAs. Select mRNA laser trabeculoplasty, a common treatment for glaucoma, ap- changes were then compared by quantitative reverse transcrip- pears to owe its efficacy to producing relatively sustained tion–polymerase chain reaction (qRT-PCR).
    [Show full text]